These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 21058730)
1. Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. Balluff B; Elsner M; Kowarsch A; Rauser S; Meding S; Schuhmacher C; Feith M; Herrmann K; Röcken C; Schmid RM; Höfler H; Walch A; Ebert MP J Proteome Res; 2010 Dec; 9(12):6317-22. PubMed ID: 21058730 [TBL] [Abstract][Full Text] [Related]
2. Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. Rauser S; Marquardt C; Balluff B; Deininger SO; Albers C; Belau E; Hartmer R; Suckau D; Specht K; Ebert MP; Schmitt M; Aubele M; Höfler H; Walch A J Proteome Res; 2010 Apr; 9(4):1854-63. PubMed ID: 20170166 [TBL] [Abstract][Full Text] [Related]
3. HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Traina A; Agostara B; Marasà L; Calabrò M; Zarcone M; Carruba G Ann N Y Acad Sci; 2006 Nov; 1089():159-67. PubMed ID: 17261764 [TBL] [Abstract][Full Text] [Related]
4. Analysis of HER2 by chromogenic in situ hybridization and immunohistochemistry in lymph node-negative breast carcinoma: Prognostic relevance. Peiró G; Aranda FI; Adrover E; Niveiro M; Alenda C; Payá A; Seguí J Hum Pathol; 2007 Jan; 38(1):26-34. PubMed ID: 17056098 [TBL] [Abstract][Full Text] [Related]
5. Intratumoral heterogeneity of HER2/neu in breast cancer--a rare event. Hanna W; Nofech-Mozes S; Kahn HJ Breast J; 2007; 13(2):122-9. PubMed ID: 17319852 [TBL] [Abstract][Full Text] [Related]
6. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Vinatzer U; Dampier B; Streubel B; Pacher M; Seewald MJ; Stratowa C; Kaserer K; Schreiber M Clin Cancer Res; 2005 Dec; 11(23):8348-57. PubMed ID: 16322295 [TBL] [Abstract][Full Text] [Related]
7. Comparison of HER2 gene amplification assessed by fluorescence in situ hybridization and HER2 protein expression assessed by immunohistochemistry in gastric cancer. Yano T; Doi T; Ohtsu A; Boku N; Hashizume K; Nakanishi M; Ochiai A Oncol Rep; 2006 Jan; 15(1):65-71. PubMed ID: 16328035 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Dandachi N; Dietze O; Hauser-Kronberger C Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190 [TBL] [Abstract][Full Text] [Related]
9. Expression of HER2/neu in primary and metastatic breast cancer. Tuziak T; Olszewski WP; Olszewski W; Pieńkowski T Pol J Pathol; 2001; 52(1-2):21-6. PubMed ID: 11505677 [TBL] [Abstract][Full Text] [Related]
10. Prognostic utility of fluorescence in situ hybridization for determining HER2 gene amplification in breast cancer. Kammori M; Kurabayashi R; Kashio M; Sakamoto A; Yoshimoto M; Amano S; Kaminishi M; Yamada T; Takubo K Oncol Rep; 2008 Mar; 19(3):651-6. PubMed ID: 18288397 [TBL] [Abstract][Full Text] [Related]
11. The role of HER2/neu overexpression/amplification in the progression of ductal carcinoma in situ to invasive carcinoma of the breast. Latta EK; Tjan S; Parkes RK; O'Malley FP Mod Pathol; 2002 Dec; 15(12):1318-25. PubMed ID: 12481013 [TBL] [Abstract][Full Text] [Related]
13. Characterizing the HER2/neu status and metastatic potential of breast cancer stem/progenitor cells. Pommier SJ; Quan GG; Christante D; Muller P; Newell AE; Olson SB; Diggs B; Muldoon L; Neuwelt E; Pommier RF Ann Surg Oncol; 2010 Feb; 17(2):613-23. PubMed ID: 19838757 [TBL] [Abstract][Full Text] [Related]
14. Testing for HER2 in breast cancer. Lewis F; Jackson P; Lane S; Coast G; Hanby AM Histopathology; 2004 Sep; 45(3):207-17. PubMed ID: 15330798 [TBL] [Abstract][Full Text] [Related]
15. The role of immunohistochemistry and fluorescence in situ hybridization for HER2/neu in assessing the prognosis of breast cancer. Mitchell MS; Press MF Semin Oncol; 1999 Aug; 26(4 Suppl 12):108-16. PubMed ID: 10482202 [TBL] [Abstract][Full Text] [Related]
16. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615 [TBL] [Abstract][Full Text] [Related]
17. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528 [TBL] [Abstract][Full Text] [Related]
18. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Xia W; Chen JS; Zhou X; Sun PR; Lee DF; Liao Y; Zhou BP; Hung MC Clin Cancer Res; 2004 Jun; 10(11):3815-24. PubMed ID: 15173090 [TBL] [Abstract][Full Text] [Related]
19. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information. Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399 [TBL] [Abstract][Full Text] [Related]
20. Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas. Hirschmann A; Lamb TA; Marchal G; Padilla M; Diebold J Am J Clin Pathol; 2012 Dec; 138(6):837-44. PubMed ID: 23161718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]